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Rapid advances in the discovery of long noncoding RNAs (lncRNAs) have identified lineage- and cancer-specific
biomarkers thatmay be relevant in the clinicalmanagement of prostate cancer (PCa). Herewe assembled and analyzed a
largeRNA-seq dataset, from585patient samples, including benign prostate tissue andboth localized andmetastatic PCa
to discover and validate differentially expressed genes associated with disease aggressiveness. We performed Sample
Set Enrichment Analysis (SSEA) and identified genes associated with low versus high Gleason score in the RNA-seq
database. Comparing Gleason 6 versus 9+ PCa samples, we identified 99 differentially expressed genes with variable
association to Gleason grade as well as robust expression in prostate cancer. The top-ranked novel lncRNA PCAT14,
exhibits both cancer and lineage specificity. Onmultivariate analysis, low PCAT14 expression independently predicts for
BPFS (P = .00126), PSS (P = .0385), and MFS (P = .000609), with trends for OS as well (P = .056). An RNA in-situ
hybridization (ISH) assay for PCAT14 distinguished benign vs malignant cases, as well as high vs low Gleason disease.
PCAT14 is transcriptionally regulated by AR, and endogenous PCAT14 overexpression suppresses cell invasion. Thus,
Using RNA-sequencing data we identify PCAT14, a novel prostate cancer and lineage-specific lncRNA. PCAT14 is highly
expressed in low grade disease and loss of PCAT14 predicts for disease aggressiveness and recurrence.
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Early detection of prostate cancer, largely facilitated by the advent of
PSA screening, has also been attributed to over-diagnosis and
overtreatment of this disease [1–3]. While coupling PSA screening
with other biomarkers such as the long non-coding RNA (lncRNA)
transcript PCA3 or gene fusions events (such as TMPRSS2-ERG)
have increased specificity of cancer diagnosis, these biomarkers have
limited utility in stratifying patients in terms of prognosis [4,5].
While stratifying patients into risk groups based on clinicopathologic
features is currently used to guide treatment decisions [6], it is clear
that current stratification approaches need to be further refined to
allow better personalization of therapy. Thus, identifying molecular
biomarkers to distinguish indolent versus aggressive disease would
address an unmet need in the clinical management of prostate cancer.
Advances in next-generation sequencing technologies have enabled
thorough characterization of cancer transcriptomes, especially in
unraveling the realm of non-coding RNAs (ncRNAs) [7,8]. In
particular, lncRNAs, a class of ncRNAs, have gained increasing
attention as biomarkers due to their tissue- and cancer-specific
expression profile [9]. In this study, we assembled and analyzed a large
RNA-seq compendium compiled from recent publications from
consortiums such as The Cancer Genome Atlas (TCGA), the Prostate
Cancer Foundation/Stand Up to Cancer international team, and
others to identify differentially expressed genes (both protein coding
and non-coding genes), that are associated with indolent versus
aggressive disease [10,11]. Our results identify PCAT14, a prostate
cancer- and lineage-specific lncRNA, as a top differentially expressed
gene in this context. We characterize PCAT14 preclinically and
demonstrate that it correlates inversely in expression with disease
aggressiveness and adds to conventional clinicopathologic risk factors
in predicting prognosis in prostate cancer patients. Finally, we
develop a novel in-situ hybiridation (ISH)-based approach for
detecting PCAT14 in clinical samples.
Material and Methods
RNA-Seq Data Set
Prostate RNA-seq cohort (n = 585) containing 52 benign prostate
tissues, 501 primary prostate cancers, and 132 metastatic prostate
cancers was used in this study. For nomination of Gleason associated
genes, we compared low Gleason tumors (Gleason 6, n = 45) to high
Gleason tumors (Gleason 9+, n = 140).
RNA-seq Data Processing
TCGA prostate Fastq files were obtained from the CGhub. Reads
were aligned using STAR version 2.4.2 [12] and read abundance was
calculated using FeatureCounts version 1.4.6 [13].
RNA-Seq Differential Expression Testing
Differential expression testing was performed using the Sample Set
Enrichment Analysis (SSEA) tool described previously [7]. Briefly,
following count data normalization, SSEA performs the weighted
KS-test procedure described in GSEA [14]. The resulting enrichment
score (ES) statistic describes the enrichment of the sample set among
all samples being tested. To test for significance, SSEA enrichment
tests are performed following random shuffling of the sample labels.
These shuffled enrichment tests are used to derive a set of null
enrichment scores (1000 null enrichment scores computed). The
nominal p value reported is the relative rank of the observed
enrichment score within the null enrichment scores. Multiplehypothesis testing is performed by comparing the enrichment score
of the test to the null normalized enrichment score (NES)
distributions for all transcripts in a sample set. This null NES
distribution is used to compute FDR q values in the same manner
used by GSEA [14]. SSEA percentile score determined by ranking the
genes in each analysis by their NES score.
Tissue Expression Heatmap Generation
The “gplots” R-package was used to generate heatmaps using the
heatmap.2 function. Expression was normalized as log2 of the
fold-change over the median of the normal samples for each
transcript. Unsupervised hierarchical clustering was performed with
the hclust function, using Pearson correlation as the clustering
distance, using the “ward” agglomeration method.
Identification of Genes Differentially Expressed in Prostate
Cancer of Varying Gleason Score
Differentially expressedGleason associated genes were identified as any
gene with an SSEA FDRb 0.01 when comparing Gleason 6 primary
tumors to Gleason 9+ primary tumors. Filtering for expression levels in
tissues was done by enforcing that each gene had N5FPKM expression in
the top 5% of prostate tumor samples. Filtering for overexpression in
cancers versus normal was done by enforcing an SSEA FDR of b0.0001
in an analysis comparing the TCGA prostate cancer vs normal tissues.
Tissue specificity percentile was determined as the SSEA percentile for
each gene in an SSEA analysis comparing the TCGA prostate samples to
all other TCGA tumors in our multi-tissue compendium [7].
Clinical Analysis
To assess the prognostic value of PCAT14, microarray data was
obtained from the Johns Hopkins University (JHU) (N = 355). Patients
were treated with prostatectomy and subsequently received no adjuvant
or salvage treatment until metastasis. Microarray processing and
normalization was performed as described previously [15]. PCAT14
expression was calculated by taking the mean expression of probe sets
mapping to exons.High/lowPCAT14was determined by splitting on the
median expression level. Kaplan–Meier curves are shown and statistical
inference was performed using the Log-rank test. Multivariate analysis
was performed using Cox regression. Age was treated as a continuous
variable. PSA was grouped into low (b10 ng/ml), intermediate
(10–20 ng/ml), and high (N20 ng/ml). Surgical margin status (SMS),
seminal vesicle invasion (SVI), extracapsular extension (ECE), and lymph
node invasion (LNI) were treated as binary variables. Gleason score was
grouped into low (≤7) or high (8–10). Association of PCAT14 and
clinicopathologic variables was evaluated using a t-test for continuous
variables, and a chi-squared test for categorical variables. Statistical
significance was set as a two-sided p-value b0.05. All analyses were
performed in R 3.1.2.
ISH Analysis
PCAT14 ISH was performed on thin (approximately 4 μm thick)
TMA sections (Advanced Cell Diagnostics, Inc., Hayward, CA), as
described previously [16,17]; in parallel, PCAT14 ISH was performed
on previously identified positive and negative control index
formalin-fixed paraffin embedded (FFPE) tissue sections. All slides
were examined for PCAT14 ISH signals in morphologically intact
cells and scored manually by a study pathologist (Rohit Mehra).
Specific PCAT14 ISH signal was identified as brown, punctate dots,
and expression level was scored as follows: 0 = no staining or less than
1 dot per 10 cells, 1 = 1 to 3 dots per cell, 2 = 4 to 9 dots per cell (few
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4 = greater than 15 dots per cell (more than 10% in dot clusters). For each
evaluable tissue core, a cumulative ISHproduct scorewas calculated as the sumof
the individual productsof the expression level (0 to4) andpercentageof cells (0 to
100) (i.e., [A% × 0] + [B% × 1] + [C% × 2] + [D% × 3] + [E% × 4];
total range = 0 to 400). For each tissue sample, the ISH product score was
averaged across evaluable TMA tissue cores. All quantitative data were shown as
mean ± S.D. To obtain significance in the difference between two groups was
performed by two-sided t test using Graph Pad Prism 6.02 software.
Cell Lines, Tissues and Reagents
All prostate cell lines used in this study were purchased from the American
TypeCultureCollection (ATCC), cultured according to their recommendations
andwere periodically checked formycoplasma contamination and genotyped to
confirm identity. For androgen treatment experiments, VCaP cells were
pre-cultured inandrogen-freecharcoal-strippedmediumfor48 hoursandtreated
with 10 nM dihydrotestosterone (DHT) or 10 μM MDV3100 or vehicle
(ethanol) for indicated time points before cells were harvested for RNA isolation.
For drug treatment experiments, LNCaP cells were treated with the 5–20 μM
DNA methylation inhibitor 5-aza-2′-deoxycytidine (5-aza) (catalog:
A3656-5MG, Sigma), or DMSO for 5 days. RNA was isolated 24 h after
drug treatment and expression was analyzed by qRT-PCR.
Prostate specimens were acquired from the patients who underwent
radical prostatectomy and from theRapid Autopsy Program at the tissue
core of University of Michigan as part of the University of Michigan
Prostate Cancer Specialized Program Of Research Excellence
(S.P.O.R.E.). Informed consents were obtained from each patient.
RNA Isolation and qPCR Analysis
Total RNAwas extracted usingTrizol reagent and anRNeasyMicro Kit
(Qiagen) with DNase I digestion according to the manufacturer's
protocols. RT-PCR was performed from total RNA using Superscript III
(Invitrogen) with random primers (Invitrogen). Quantitative PCR (qPCR)
was performed using Fast SYBR Green Master Mix (Applied Biosystems)
on a 7900HT Fast Real-Time PCR system (Applied Biosystems). All
oligonucleotide primers were purchased from Integrated DNA Technol-
ogies (Coralville, IA) are sequence of each primer is listed in Supplementary
Table 4. Primer specificity was determined by sequence verifying the PCR
products using the University of Michigan Sequencing Core facility.
Rapid Amplification of cDNA Ends (RACE)
5′ and 3′ RACE was performed using the GeneRacer RLM-RACE
kit (Invitrogen) according to the manufacturer's protocols. RACE
PCR products obtained using Platinum Taq high-fidelity polymerase
(Invitrogen), were resolved on a 1.5% agarose gel. Individual bands
were gel purified using a Gel Extraction kit (Qiagen), and cloned into
PCR4 TOPO vector, and sequenced using M13 primers.
Knock Down Studies
MDA-PCa-2b and VCaP cells were seeded in biocoated 6-well
plates at 60% confluency, incubated overnight, and transfected with
50 nM siRNAs targeting different exons of PCAT14 or non-targeting
siRNAs, using RNAi MAX reagent (Invitrogen) per manufacturer's
instructions. RNA was harvested 48 h after transfection. Functional
experiments were performed at indicated time points. Sequence of all
the siRNA used in shown in Supplementary Table 4.
Nuclear-Cytoplasmic Subcellular Fractionation
Nuclear-cytoplasmic fraction of MDA-PCa-2b and VCaP cells was
performed using an NE-PER Nuclear and Cytoplasmic Extraction kit(Thermo Scientific) following manufacturer's instructions, followed
by RNA isolation and qPCR analysis.
CRISPR Based Overexpression of PCAT14
Stable cell lines overexpressing PCAT14 endogenously were made using
previously published protocol [18]. Briefly, guide RNAs targeting promoter
region ofPCAT14 (SupplementaryTable 4)were designed using online tool at
http://crispr.mit.edu/ and cloned into sgRNA-MS2 vector using lenti
sgRNA(MS2) zeo backbone. Lentiviral particles expressing PCAT14
sgRNA-MS2 were generated by the University of Michigan vector core. To
generate LNCaP or PC3 cell over expressing PCAT14, first cells were seeded
into 100 mm dish and transduced with Lenti dCAS-VP64 (blasticidin) and
Lenti-MS2-p65-HSF1 (hygromycin) vectors. After 2 days, cells were selected
with 4 μg/ml Blasticidin and 200 μg/ml Hygromycin. Cells stably expressing
dCAS-VP64 andMS2-p65-HSF1 cells were then seeded in 6-well plates and
infected with PCAT14 sgRNA-MS2 lentivirus. 24 hours later, cells were
selected with triple antibiotics: 4 μg/ml Blasticidin, 200 μg/ml Hygromycin
and 800 μg/ml Zeomycin for 1 week. Expression of PCAT14 in these cells
was verified by qPCR.
In Vitro FluoroBlok Tumor Invasion Assay
The In vitro FluoroBlok Tumor Invasion Assay (BD) was performed as
previously described [19]. Briefly, after rehydration of the BD FluoroBlok
membrane, 500ul of serum-freeRPMImediumresuspendedprostate cancer
cells (PC3, 50,000 cells per well, or LNCaP, 100,000 cells per well) were
seeded into the apical chambers. 750ulRPMImediumcontaining10%FBS
were added to the basal chamber as chemoattractant. Then plates were
incubated at 37 °C, 5% CO2 for 24 hours. Following incubation, medium
from the apical chambers were removed, and the inserts were transferred to a
24-well plate containing 500ul/well of 4ug/mL Calcein AM (Invitrogen) in
Hanks buffered saline. Plates were incubated for 1 hour at 37 °C, 5%CO2,
then pictures of invaded cells were taken by using inverted fluorescence
microscope (Olympus), and quantified by ImageJ software [20].Oncomine Concepts Analysis of the PCAT14 Signature
Gene that positively correlated (R2 N 0.35, n = 591) with PCAT14 in
TCGA RNA-seq data were selected and uploaded into Oncomine database
[21] as custom concepts (Supplementary Table 2). All the prostate cancer
concepts with odds ratioN 2.0 and p-value b1 × 10−4 were selected. For
simplicity, top4 concepts (basedonodds ratios)were selected for representation.
We exported these results as the nodes and edges of a concept association
network and visualized the network using Cytoscape version 3.3.0. Node
positions were computed using the Edge-weighted force directed layout in
Cytoscape using the odds ratio as the edge weight. Node positions were subtly
altered manually to enable better visualization of node labels.
Statistics
All quantitative data were shown as mean ± S.D. To obtain
significance in the difference between two groups was performed by
two-sided t test or ANOVA using Graph Pad Prism 6.02 software.
Results
Identification of Genes Associated With Gleason Grade in
Prostate Cancer
Comprehensive molecular characterization of common cancer
types has become feasible with the recent availability of large next
generation sequencing datasets on tumor tissues. To identify genes
(both coding and non-coding) associated with aggressive prostate
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containing 52 benign prostate tissues, 501 primary prostate cancers,
and 132 metastatic prostate cancers. We performed differential
expression testing utilizing a non-parametric tool we developed for
RNA-seq data called Sample Set Enrichment Analysis [7]. In order toFigure 1. Identification of lncRNA PCAT14 as a prostate cancer biomar
highly-expressed, prostate cancer specific genes associated with low
coding genes differentially expressed (n = 99) between Gleason
expression of these genes in benign and metastatic prostate cancer t
is depicted as log2 of the fold-changeover themedian of theGleason 6 sa
score. Rows represent genes and columns represent samples. C. Sca
prostate cancer association of protein coding (solid circle) and lncRNA (s
FPKM value for the 95th percentile prostate cancer sample. Cancer v
percentile score for each gene in an SSEA analysis. D. The top five,
specificity. E. Expression ofPCAT14 across all cancer and normal tissue
PCAT14 genomic location.nominate the most intriguing biomarkers associated with aggressive
disease, we compared low Gleason tumors (Gleason 6, n = 45) to
high Gleason tumors (Gleason 9+, n = 140) and applied filters for
substantial expression in prostate tumor tissue (N5PKM in the top
5% of prostate samples), and significant differential expression inker. A. Schematic representation of the workflow utilized to identify
-Gleason disease. B. Heatmap depiction of the lncRNA and protein
6 versus 9+ analysis in TCGA prostate RNA-seq data. Relative
issues [11] are also displayed alongside for comparison. Expression
mples for eachgene. Patients grouped by cancer progression/Gleason
tterplot showing the expression level, prostate tissue specificity, and
olid triangles) genes identified in 1 A. Expression is represented by the
ersus normal and prostate tissue specificity are represented by the
Gleason 6 associated genes listed in the order of prostate tissue
type represented in the TCGA. Inset shows genome browser view of
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a total of 99 candidates genes (Figure 1A, Supplementary Table 1).
Interestingly, clustering analysis revealed signature expression
patterns, specifically associated with low, high Gleason and metastatic
status and included both novel and previously characterized genes
(Figure 1B). CENPF and EZH2, protein coding genes with a known
association with high grade prostate cancer were rediscovered through
this analysis [22,23]. Similarly, we rediscovered SChLAP1 a long
non-coding RNA (lncRNA) associated with aggressive prostate
cancers [15,17] in our analysis (Figure 1B). With the goal of
identifying potential biomarkers that distinguish indolent prostate
cancers, we focused on genes enriched in low grade disease that are
expressed highly in prostate tissue and that also show prostate cancer
and tissue specificity (Figure 1C). Interestingly, a lncRNA, PCAT14
appeared to be one of the top low-Gleason-associated genes with
robust prostate tissue expression, substantial prostate tissue specific-
ity, and significant overexpression in prostate cancers versus normal
(Figure 1D). In fact, among all genes (coding and non-coding),
PCAT14 ranked among the top 5 in terms of expression level,
Gleason 6 versus 9+ association, and cancer versus normal association
(Figure 1D). Additionally, among the top 5 candidate genes,
PCAT14 was the only gene to exhibit striking prostate tissue
specificity, a particularly relevant metric for a potential biomarker
(Figure 1E). The remaining 4 genes exhibited variable prostate tissue
specificity (Supplementary Figure 1). PCAT14 is a poly-exonic gene
found within a gene desert on chromosome 22, with a striking
prostate cancer and lineage specific expression pattern across the
N10,000 TCGA cancer and normal tissue samples (Figure 1E). For
these reasons, we elected to pursue PCAT14 as a promising biomarker
that can identify low grade prostate cancer.
Genomic Organization and Regulation of PCAT14
We collected multiple lines of evidence from both experimental
data and available annotations to consolidate the genomic organiza-
tion of PCAT14. Based on assembled reads from RNA-seq data
assembled in the MiTranscriptome [7], we predicted the structure of
the PCAT14 transcript variants (Supplementary Figure 1A).
Additionally, as an independent approach to define the exon structure
of PCAT14, we performed rapid amplification of cDNA ends
(RACE) in two prostate cancer cell lines VCaP and MDA-PCa-2b
that express PCAT14 at high levels (Supplementary Figure 1B and
C). Our analyses show that the PCAT14 gene is located on
chr22-q11.2 and contains 4 exons. Among the four transcript
isoforms, the 2.3 kb variant-1 demonstrates the highest expression
(Supplementary Figure 1D). Next, using published ChIP-seq data in
VCaP cells [24], we show that PCAT14 has all the histone marks
(H3K4me3, H3K36me3, H3K27ac) associated with actively tran-
scribed genes (Figure 2A). We further performed subcellular
fractionation followed by qPCR to show that PCAT14 is distributed
equally between nuclear and cytoplasmic compartments (Figure 2B).
Androgen receptor plays a major role To identify any potential
regulation of PCAT14 gene by androgen, we assessed the presence of
AR peaks in PCAT14 genomic region using AR-ChIP-seq data
generated in VCaP cells [24] and saw significant AR peaks in PCAT14
loci. Some of these peaks were also enhanced upon treatment with
DHT and were suppressed upon treatment with AR antagonist
MDV3100 or bicalutamide (Figure 2C). To corroborate this finding,
we assessed the expression of PCAT14 mRNA in VCaP cells upon AR
stimulation. Similar to the canonical AR targets such as KLK3 andFKBP5, PCAT14 expression was also significantly elevated (four fold in
24 hours) upon DHT stimulation (Figure 2D) and suppressed by
MDV3100 treatment (Figure 2E). In another line of investigation, we
queried if epigenetic regulation might play a role in the prostate cancer
and lineage specific expression of PCAT14 observed in tissue samples
(Figure 1E). Using a prostate cancer cell line (LNCaP) model we show
significant elevation of PCAT14 expression when treated with
5-azacytidine (5-Aza), a DNA demethylation agent, suggesting a
potential role for promoter methylation in regulation of PCAT14
(Figure 2F). However, our attempt to capture this event in TCGA
tissue samples where Infinium 450 K DNA methylation array data is
available was inconclusive, due to the lack of probes in PCAT14
promoter region. Taken together we showPCAT14 is an AR target gene
that may also be subjected to epigenetic regulation in prostate cancer.
Clinical Association of PCAT14
Having observed an inverse correlation of PCAT14 with Gleason
Score (GS) in our RNA-seq cohort, we next assessed the association of
PCAT14 expression with clinical outcomes in prostate cancer. For this
analysis we first divided samples into 7 groups (benign, GS-6, GS-7
(3 + 4), GS7 (4 + 3), GS-8, GS-9 and Mets) and examined the
expression of PCAT14 using two different datasets (TCGA and Taylor
et al.). We identified a significant decrease in PCAT14 expression as
Gleason grade increased in both cohorts (Figure 3A and B).
Importantly, in the large TCGA dataset, expression was significantly
different between GS6 and all other groups except GS7 (3 + 4). We
next assessed the diagnostic ability of PCAT14 to identify prostate
cancers versus normal. In both the TCGA and Taylor prostate cancer
cohorts, PCAT14 expression was able to significantly distinguish cancer
from normal with an AUC of 0.837 and 0.823 respectively (Figure 3C)
supporting its utility as a diagnostic biomarker.
Using an alternate approach to further characterize the clinical
associations of PCAT14, we performed a “guilt-by-association”
analysis, assessing the clinical significance of the protein-coding
genes most correlated with PCAT14 (Supplementary Table 2) in the
TCGA prostate cancer cohort, leveraging cancer microarray data from
the Oncomine resource [21]. As expected, genes positively correlated
with PCAT14 were upregulated in cancer vs normal analysis and were
downregulated in clinically advanced prostate cancer (Figure 3D).
Interestingly, we found a striking association of PCAT14 correlated
genes with concepts related to better prognosis (Figure 3D), and these
genes were under-expressed in recurrent and hormone refractory
prostate cancer suggesting thatPCAT14may be amarker of better clinical
outcomes in prostate cancer. In contrast, genes that positively correlated
with SChLAP1, a lncRNA known to be associated with clinically
aggressive prostate cancer, were found to be overexpressed in advanced
prostate cancer as well as in cancer with poor outcomes [15,17].
To further investigate the association of PCAT14 with favorable
clinical outcomes in prostate cancer, we performed Cox regression
analysis on a cohort of 355 patients (John Hopkins University (JHU)
cohort) who did not receive treatment prior to metastasis (median
follow-up 9 years). Univariate analysis showed that, patients with
high PCAT14 expression were significantly associated with better
BPFS (P = .000062; HR = 0.59 [0.45–0.76]), MFS (P = .00016;
HR = 0.46 [0.32–0.66]), PSS (P = .0067; HR = 0.47[0.27–0.82])
and OS (P = .022; HR = 0.57 [0.35–0.93]) (Figure 4A-D). In a Cox
multivariate analysis including clinicopathologic variables, PCAT14
stands out as a significant independent predictor of PSS (P = .0385;
HR = 0.55 [0.31–0.97]), MFS (P = .000609; HR = 0.52[0.36–0.76])
Figure 2. Subcellular localization and regulation of PCAT14. A. Genome browser view of PCAT14 locus. ChIP-seq tracks for H3K4me3,
H3K27ac, H3K36me3 and Pol-II generated in prostate cancer VCaP cells are shown. Prostate RNA-seq reads, transcript schematic based
on RACE results and Refseq, GENCODE, MiTranscriptome assembly annotations are also provided. Solid blocks indicate exons while thin
lines intron and arrows indicate the genomic orientation. B. Bar plots represent the subcellular localization of PCAT14 in prostate cell lines.
PCAT14 transcript was equally found in both cytoplasmic (red) and nuclear (blue) compartments in both MDA-PCa-2b and VCaP cell lines.
GAPDH and U1 RNA were used as controls. C. Genome browser view of the PCAT14 genomic locus for AR ChIP-seq data tracks obtained
from VCaP cells treated with either vehicle (black) or dihydrotestosterone (DHT) alone (Red) or combinations (dark blue) including
DHT + MDV3100 and DHT + Bicalutamide. Significant AR binding observed in each data track are represented as peaks. D-E.
Histograms represent the expression of PCAT14, TMPRSS2 and KLK3 in VCaP cells after treatment with 10 nM DHT or with MDV3100 for
indicated time points. F. Bar plots represent re-expression of PCAT14 and GSTP1 in LNCaP cells after treatment with 5-Aza deoxycytidine
(5-Aza) for 5 days at indicated concentrations.
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significance for OS (Table 1, Supplementary Table 3). In addition, we
also analyzed the association ofPCAT14 expression with clinical outcome
in two independent data sets of 140 (Taylor et al) and 377 (TCGA)
patients using the statistical approaches mentioned above [25]. Similar
to JHU cohort, high PCAT14 expression predicted for better BRFS
(Figure 4E) and MFS (Figure 4F). We also show that high PCAT14
expression was predictor of better prognosis in lower Gleason grade
samples (Supplementary Figure 3B).PCAT14 Expression In-Situ
LncRNA detection in cancer tissue sections by RNA in-situ
hybridization (RNA-ISH) technology has similar clinical utility as
immunohistochemical evaluation of protein biomarkers [16,26].
Hence we evaluated PCAT14 transcript levels in PCa FFPE tissues
using specific probes to perform a RNA-ISH. We first probed a panel
of FFPE sections derived from either murine prostate, kidney, lung
(negative controls) or xenografts from MDA-PCa-2b cells, a cell line
that expresses PCAT14 at high levels (positive control). As expected,
Figure 3. PCAT14 is marker of low grade tumros. A-B. Expression of PCAT14 in samples distinguished by Gleason grade in TCGA (A),
Taylor (B) cohorts. (* = P b .05, ** = P b .01, **** = P b .0001; compared to Gleason 6). C. ROC analysis of PCAT14 expression in
the TCGA and Taylor cohorts. D. Network representation of genes positively correlated with PCAT14 in localized prostate cancers using
Oncomine concepts analysis and visualized with the Force-Directed Layout algorithm in the Cytoscape tool [29]. Node names are
assigned according to the author of the primary study [25,30–38]. Nodes are colored according to the concept categories indicated in the
figure legend. Thickness of the edges implies higher odds ratio.
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while no expression/staining was seen in the negative control murine
tissues (Supplementary Figure 5A and B). Consistent with the cell
fractionation data, expression of PCAT14 was seen in both nuclear
and cytoplasmic compartments. Next we obtained frozen and
matched formalin fixed paraffin embedded (FFPE) tissues sections
derived from a patient radical prostatectomy specimen with Gleason
score 3 + 3 = 6 disease. q-PCR analysis on cDNA from frozen tissues
derived from this specimen shows a 7–8 fold increase in PCAT14
expression in cancer compared to the adjacent benign tissue (Figure 5A).
RNA-ISH also demonstrated that PCAT14 is differentially expressed in
PCa as we saw striking difference of transcript expression with
high signals located in the prostatic adenocarcinoma glands and with
no/minimum staining in the benign section (Figure 5B). To further
expand these results, we performed RNA-ISH on a PCa tissue
microarray (TMA, n = 129) (Figure 5C) and found that PCAT14
expression was able to distinguish tumor from normal (AUC 0.863)
(Figure 5D) and was high in Gleason-6 with minimal expression noted
in benign tissue or Gleason 8 disease (Figure 5E).Functional Evaluation of PCAT14
Since expression of PCAT14 was lower in high grade prostate
cancer and its expression predicted better outcomes, we hypothesize
that PCAT14 may have tumor suppressive effects. To test this
hypothesis, we performed overexpression studies in PC3 and LNCaP
cells, prostate cancer cell lines that do not express PCAT14
(Supplementary Figure 2B, C). To overexpress PCAT14, we used a
CRISPR (clustered regularly interspaced short palindromic repeat)-
Cas9 Synergistic Activation Mediator (SAM) complex [18]. This
method allows endogenous overexpression of a gene by recruiting
artificial transcriptional factors to the promoter using single-guide
RNA (sgRNA-MS2) (See method section for details). We designed 6
sgRNAs targeting the PCAT14 promoter and tested their ability to
induce PCAT14 expression using HEK293 cells stably expressing
transcription factors. We found three sgRNAs that significantly
increased PCAT14 expression in HEK293 cells (Supplementary Figure
5A).We next used these sgRNA to construct PC3 and LNCaP cells stable
expressing PCAT14 (Figure 6A). Using two independent sgRNAs we
were able to achieve 500 to 1000-fold endogenous overexpression of
Figure 4. PCAT14 is a prognostic biomarker. A-D. Kaplan–Meier analyses of prostate cancer outcomes in the John Hopkins cohort.
PCAT14 expression was measured using Affymetrix exon arrays, and subjects were stratified according to their PCAT14 expression level.
Subject outcomes were analyzed for biochemical progression (D) andMetastasis free survival (E), Prostate cancer-specific survival (F) and
overall survival (G). Subject outcomes were analyzed for Kaplan–Meier curves, P values determined using a log-rank test. E-F. Kaplan–
Meier analyses of biochemical progression free survival in the Taylor (E) and Metastasis Free survival in the TCGA (F) cohorts of prostate
cancer. Patients were divided into two groups based on the expression level of PCAT14. P values for Kaplan–Meier curves were
determined using a log-rank test.
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LNCaP cells (Supplementary Figure 5B). While we observed no
significant effect of PCAT14 overexpression on proliferation of PC3 or
LNCaP cells (Figure 6C and Supplementary Figure 5C), overexpressionTable 1. Multivariate Analysis in JHU Cohort
Biochemical Recurrence Free Survival Metastasis Free Survival
P-Value HR [95% CI] P-Value HR [
PCAT14 High vs. Low .00126 0.64 [0.49–0.84] .000609 0.52
Age .818 1 [0.98–1.02] .65 0.99
PSA Int vs. Low .241 0.83 [0.62–1.13] .353 0.83
PSA High vs. Low .916 0.98 [0.63–1.52] .574 0.84
Gleason High vs. Low 2.98E-05 1.83 [1.38–2.43] 1.00E-08 3.08
Seminal vesicle invasion .0042 1.52 [1.14–2.03] .453 1.16
Surgical margin status .000533 1.78 [1.28–2.47] .000276 2.15
Extracapsular extension .456 1.14 [0.81–1.58] .459 1.21
Lymph node invasion 8.98E-12 3.23 [2.31–4.52] .000164 2.21
HR: Hazard Ratioof PCAT14 lead to suppression of invasion capacity of both PC3 and
LNCaP cells (Figure 6C,D; Supplementary Figure 5E, F), in line with its
prior identified association with clinically indolent disease. We then
looked at the effects of PCAT14 knockdown on cell expressingProstate Cancer Free Survival Overall Survival
95% CI] P-Value HR [95% CI] P-Value HR [95% CI]
[0.36–0.76] .0385 0.55 [0.31–0.97] .0567 0.62 [0.38–1.01]
[0.96–1.02] .338 0.98 [0.93–1.02] .151 0.97 [0.93–1.01]
[0.55–1.24] .385 0.75 [0.4–1.42] .366 0.77 [0.44–1.35]
[0.47–1.52] .463 0.73 [0.31–1.7] .582 0.81 [0.39–1.7]
[2.1–4.52] .000224 3.1 [1.7–5.65] .000988 2.38 [1.42–3.99]
[0.79–1.69] .774 0.92 [0.51–1.66] .82 0.94 [0.56–1.59]
[1.42–3.25] .0487 1.93 [1–3.7] .0825 1.67 [0.94–2.99]
[0.73–2.03] .636 0.83 [0.39–1.77] .816 0.93 [0.48–1.77]
[1.46–3.35] .0616 1.86 [0.97–3.57] .254 1.42 [0.78–2.6]
Figure 5. PCAT14 RNA-ISH in prostate cancer tissues. A. Barplot to show the expression of PCAT14 in tumor tissue and adjacent benign
by qRT-PCR. B. A representative PCAT14 RNA in-situ hybridization image. White arrows indicate Gleason score 6 disease and black
arrows indicate benign glands. C. Representative PCAT14 In situ hybridization images of human prostate cancer samples of different
Gleason grades. D. ROC analysis of PCAT14 expression in the prostate TMAs. E. Representation of mean PCAT14 ISH product score for
benign prostatic glands (benign), Gleason score 6, Gleason score 3 + 4 = 7, Gleason score 4 + 3 = 7 and Gleason score 8+ clinically
localized prostate cancer in a TMA cohort. (** = P b .01; compared to benign).
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MDA-PCa-2b and VCaP cells using 2 independent siRNA as well as
8 independent ASOs we were able to achieve more than 80%
knockdown efficiency (Supplementary Figure 5G-J). However, we did
not observe a consistent effect on cell proliferation as well as cell invasion
(Supplementary Figure 5K-N and data not shown).
Discussion
In this study, we perform a large-scale RNA-sequencing-based
analysis of biomarkers associated with indolent versus aggressive
prostate cancer and identify the long noncoding RNA PCAT14 as a
marker of low grade and indolent disease. We define the exon
structure of PCAT14 and demonstrate that PCAT14 is an
AR-regulated lncRNA. Using two independent data sets, we show
that PCAT14 is highly upregulated in prostate cancer compared to
benign tissue and is able to distinguish prostate cancer from normal
tissue with high sensitivity and specificity, suggesting that PCAT14
can be an excellent diagnostic biomarker. Moreover, we demonstrate
that expression of PCAT14 is prognostic of outcome and is associatedwith better biochemical progression-free survival, metastases-free
survival, and prostate cancer-specific survival. Importantly, we find
that PCAT14 expression is a prognostic biomarker which adds to
standard clinicopathologic variables.
As such, PCAT14 represents a unique biomarker. Most diagnostic
biomarkers, such as PCA3, can distinguish cancer from normal tissue,
but are not prognostic [4]. Conversely, many prognostic biomarkers,
such as Ki-67, hold little diagnostic value. It is unclear why PCAT14
increases significantly in expression during the initial formation of
cancer, but then subsequently decreases in expression in disease
aggressiveness; this observation requires follow up with further
mechanistic studies but is also a feature that gives PCAT14 value as a
biomarker across multiple clinical contexts. Of note, PCAT14 was
also found to be expressed in testicular cancer samples along with
prostate cancer, suggesting the role of PCAT14 in the testicular
cancer pathogenesis. However, due to lack of normal testis samples in
the TCGA database, it is unclear, at this point, whether PCAT14 is
differentially regulated in testicular cancer compared to normal testis.
Recently, the Genotype-Tissue Expression (GTEx) program has
Figure 6. Functional analysis is PCAT14. A. Schematic representation of the workflow to endogenously overexpress PCAT14 in prostate
cancer cells using CRISPR/SAM system. B. Bar plots represent fold increase in PCAT14 level in PC3 cells expressing dCas9–VP64 and
MS2–p65–HSF1 with control or 2 independent PCAT14 sgRNAs. C. Bar plot represent quantification of invaded PC3 cells with or without
PCAT14 expression. D. Representative images of invaded PC3 cells with or without PCAT14 expression.
498 PCAT14 prognosticates prostate cancer Shukla et al. Neoplasia Vol. 18, No. 8, 2016generated a large amount of high throughput sequencing data on
normal tissue including testis [27]. This data would be useful to look
at the role of PCAT14 in testicular carcinoma.
In an attempt to develop a clinical grade assay to detect expression
of PCAT14, we developed a novel assay, using ISH probes, which can
be applied to formalin fixed paraffin-embedded tissues. This ISH
assay provides an opportunity to validate our findings in larger
cohorts with associated clinical data in the future. Ultimately, an
optimized approach for predicting indolent versus aggressive disease
will include both clinicopathologic parameters integrated with
molecular biomarkers. It is likely that this molecular assay will
involve multiplexing multiple biomarkers, and may require combining
both tissue-based and urine-based biomarkers. Potential intriguing
subsequent studies include the assessment of PCAT14 and other
candidate lncRNAs, in addition to PCA3, as urine biomarkers.
There are a several limitations to our study. While we demonstrate
the potential value of PCAT14 expression as a biomarker, it is unclear
how PCAT14 is modulating oncogenic phenotypes, from a
mechanistic perspective. Additionally, while we demonstrate the
relative specificity of PCAT14 for both prostate and testicular cancers,
the molecular basis underlying this specificity remains to be
elucidated. It is known that AR can regulate expression of genes in
both prostatic and testicular tissues, but we do not know whether the
relative cancer-specificity can be attributed to AR. Clearly, these are
important areas for future study.
Overall, our study highlights the need to look at both conventional
protein-coding genes and noncoding genes in the search for optimal
biomarkers. To our knowledge, there are approximately 20,000
protein coding genes [28], which comprise 2% of the genome. Given
our recent study demonstrating that there are close to 60,000 long
noncoding RNAs (lncRNAs) [7], many of which are specific tocertain cancers, it is clear that these lncRNAs present a relatively
underexplored frontier for biomarker development, and that
PCAT14 may represent an initial candidate to be further explored
along this frontier.
Conclusion
By performing differential expression analysis between prostate cancer
with low vs high Gleason scores, we identified lncRNA PCAT14 as a
prostate cancer- and lineage- specific biomarker of indolent disease.
We show that PCAT14 is an AR-regulated transcript and its
overexpression suppresses invasion of prostate cancer cells. Moreover,
in multiple independent datasets, PCAT14 expression associates with
favorable outcomes in prostate cancer and adds prognostic value to
standard clinicopathologic variables.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.07.001.
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